Journal profile · Oncology
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
ISSN 0277-3732 · eISSN 1537-453X · Lippincott Williams and Wilkins Ltd. · UNITED STATES · Bimonthly · Founded 1982
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 1.71; hybrid open access; review 4–8 weeks (community reports); community-reported acceptance: fairly easy; 126 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS is published by Lippincott Williams and Wilkins Ltd. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Cancer Treatment and Pharmacology, Lung Cancer Research Studies and Lung Cancer Treatments and Mutations, together about 19.4% of its articles. Its main subfields are Pulmonary and Respiratory Medicine and Oncology. (generated from OpenAlex topic counts and CAS ranking data)
Lung cancer remains one of the leading causes of cancer-related mortality worldwide, underscoring the urgent need for improved diagnostic and predictive methodologies. The several challenges in the complexity and high dimensionality of genomic data can lead to overfitting and computational inefficiencies, making it difficult to extract relevant features. The objective of this study is to develop a hybrid deep learning model that effectively integrates genomic data and imaging to enhance the accuracy of lung cancer prediction.
From the journal's Aims & Scope
Research area (LetPub): Oncology
Editor-in-chief David E. WazerPublisher website
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer Treatment and PharmacologyMedicine7%
- Lung Cancer Research StudiesMedicine6.4%
- Lung Cancer Treatments and MutationsMedicine6%
- Breast Cancer Treatment StudiesBiochemistry, Genetics and Molecular Biology5.7%
- Head and Neck Cancer StudiesMedicine5.4%
- Advanced Radiotherapy TechniquesPhysics and Astronomy4.8%
- Colorectal Cancer Treatments and StudiesMedicine4.2%
- Lung Cancer Diagnosis and TreatmentMedicine3.9%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 1.71LetPub ·
- Impact factor (publisher)
- 1.8Publisher website ·
- CiteScore 2026-06
- 2.7LetPub ·
- SJR 2026-06
- 0.65LetPub ·
- SNIP 2026-06
- 0.64LetPub ·
- h-index
- 72LetPub ·
- h-index
- 111OpenAlex ·
- i10-index
- 3,228OpenAlex ·
- 2-year mean citedness
- 1.53OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 10.93%LetPub ·
Volume
- Articles per year
- 86LetPub ·
Articles by year OpenAlex count · 6,204 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 91 | 12 | 12 |
| 2025 | 126 | 9 | 181 |
| 2024 | 80 | 13 | 260 |
| 2023 | 106 | 27 | 611 |
| 2022 | 89 | 28 | 507 |
| 2021 | 100 | 17 | 871 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref
Not usableThis publisher's "received" date is mostly when the revised manuscript arrived (42% of articles were "accepted" within 3 days), so it cannot measure review time
Other sources
- Average review time (community reports)
- 4–8 weeksLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Lippincott Williams and Wilkins Ltd.
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Bimonthly
- Founded
- 1982
- ISSN
- 0277-3732
- Electronic ISSN
- 1537-453X
- Latest issue on the website
- Volume 49, Issue 9 (September 2026)
- Official links
- Journal homepage ↗LetPub
- Submission system ↗Publisher website
FAQ
Frequently asked questions about AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
What CAS zone is AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS in?
In the 2025 upgraded edition of the CAS Journal Ranking, AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS is in Zone 4 of Medicine, and in Zone 4 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS?
The latest impact factor listed by LetPub is 1.71; CiteScore 2.7, h-index 111.
How long does peer review take at AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS?
Authors report an average review time of 4–8 weeks; the community-reported acceptance is “Fairly easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS?
According to LetPub and DOAJ records, AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS is indexed in SCIE and Scopus.
Is AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS open access, and what is the APC?
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .